%0 Journal Article
%T Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
%A Heimall J
%A Buckley RH
%A Puck J
%A Fleisher TA
%A Gennery AR
%A Haddad E
%A Neven B
%A Slatter M
%A Roderick S
%A Baker KS
%A Dietz AC
%A Duncan C
%A Griffith LM
%A Notarangelo L
%A Pulsipher MA
%A Cowan MJ
%J Biol Blood Marrow Transplant
%V 23
%N 8
%D Aug 2017
%M 28479164
%F 5.609
%R 10.1016/j.bbmt.2017.04.026
%X Severe combined immunodeficiency (SCID) is effectively treated with hematopoietic cell transplantation (HCT), with overall survival approaching 90% in contemporary reports. However, survivors are at risk for developing late complications because of the variable durability of high-quality immune function, underlying genotype of SCID, comorbidities due to infections in the pretransplantation and post-transplantation periods, and use of conditioning before transplantation. An international group of transplantation experts was convened in 2016 to review the current knowledge of late effects seen in SCID patients after HCT and to develop recommendations for screening and monitoring for late effects. This report provides recommendations for screening and management of pediatric and adult SCID patients treated with HCT.